The effect of nefazodone on comorbid anxiety symptoms associated with depression: Experience in family practice and psychiatric outpatient settings

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 2, 1996, Pages 10-14

  Zajecka, John M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; NEFAZODONE; PLACEBO; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FAMILY MEDICINE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; COMMUNITY MENTAL HEALTH SERVICES; COMORBIDITY; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; FAMILY PRACTICE; FEMALE; HUMANS; IMIPRAMINE; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES;

EID: 0029863333     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Roth M, Gurney C, Garside RF, et al. Studies in the classification of disorders: the relationship between anxiety states and depressive illnesses. Br J Psychiatry 1972;121:147-161
2. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 1983,44(8, sec 2):8-11
3. Clayton PJ, Grove WM, Coryell W, et al Follow-up and family study of anxious depression. Am J Psychiatry 1991;148:1512-1517
4. Fawcett J. Predictors of early suicide: identification and appropriate intervention. J Clin Psychiatry 1988;49(suppl 10):7-8
5. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990;147:1189-1194
6. Zubenko GS, Cohen BM, Lipinski JF. Antidepressant-related akathisia. J Clin Psychopharmacol 1987;7:254-257
7. Wirshing WC, Van Putten T, Rosenberg J, et al. Fluoxetine, akathisia, and suicidality: is there a causal connection? [letter] Arch Gen Psychiatry 1992; 49:580-581
8. Pohl R, Yeragani VK, Balon R, et al. The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988;49: 100-104
9. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991;52: 491-493
10. Eison A, Eison M, Torrente J, et al. Nefazodone: preclinical pharmacology of a new antidepressant, Psychopharmacol Bull 1990;26:311-315
11. Fawcett J, Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995;56(suppl 6):37-42
12. Guy W ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health: 1976
13. Fontaine R, Ontiveros A, Elie R, et al. A double-bund comparison of nefazodone. imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-241
14. Rickels K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994;164: 802-805
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
16. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry 1978;35:773-782
17. Taylor DP, Carter RB, Eison AS, et al Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995;56 (suppl 6):3-11